Santen Pharmaceutical Co., Ltd. (SNPHF)
USD 10.53
(0.0%)
USD 10.53
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 163.87 Billion JPY | 7.6% |
| 2023 | 166.08 Billion JPY | 6.07% |
| 2022 | 156.58 Billion JPY | 3.44% |
| 2021 | 151.38 Billion JPY | 3.18% |
| 2020 | 146.72 Billion JPY | 2.42% |
| 2019 | 143.26 Billion JPY | 3.39% |
| 2018 | 138.56 Billion JPY | 11.63% |
| 2017 | 124.13 Billion JPY | 1.36% |
| 2016 | 122.46 Billion JPY | 16.12% |
| 2015 | 105.45 Billion JPY | 16.45% |
| 2014 | 90.55 Billion JPY | 16.75% |
| 2013 | 77.56 Billion JPY | -1.85% |
| 2012 | 79.03 Billion JPY | 3.48% |
| 2011 | 76.37 Billion JPY | 0.65% |
| 2010 | 75.88 Billion JPY | 15.55% |
| 2009 | 65.67 Billion JPY | -1.81% |
| 2008 | 66.88 Billion JPY | 2.89% |
| 2007 | 65 Billion JPY | 1.78% |
| 2006 | 63.86 Billion JPY | 8.27% |
| 2005 | 58.98 Billion JPY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 FY | 163.87 Billion JPY | -1.33% |
| 2024 Q1 | 42.36 Billion JPY | -18.14% |
| 2024 Q4 | 45.08 Billion JPY | 0.46% |
| 2024 Q3 | 44.88 Billion JPY | 2.04% |
| 2024 Q2 | 43.98 Billion JPY | 3.83% |
| 2023 Q1 | 37.12 Billion JPY | -14.63% |
| 2023 Q3 | 41.32 Billion JPY | 15.15% |
| 2023 FY | 166.08 Billion JPY | 6.07% |
| 2023 Q4 | 51.75 Billion JPY | 25.23% |
| 2023 Q2 | 35.88 Billion JPY | -3.34% |
| 2022 Q3 | 37.2 Billion JPY | -1.65% |
| 2022 Q2 | 37.83 Billion JPY | -0.61% |
| 2022 Q1 | 38.06 Billion JPY | -16.34% |
| 2022 Q4 | 43.48 Billion JPY | 16.89% |
| 2022 FY | 156.58 Billion JPY | 3.44% |
| 2021 Q1 | 32.82 Billion JPY | -15.31% |
| 2021 FY | 151.38 Billion JPY | 3.18% |
| 2021 Q3 | 36.68 Billion JPY | 0.85% |
| 2021 Q4 | 45.49 Billion JPY | 24.0% |
| 2021 Q2 | 36.37 Billion JPY | 10.83% |
| 2020 FY | 146.72 Billion JPY | 2.42% |
| 2020 Q4 | 38.75 Billion JPY | 3.36% |
| 2020 Q3 | 37.49 Billion JPY | 5.75% |
| 2020 Q1 | 35.01 Billion JPY | -12.17% |
| 2020 Q2 | 35.45 Billion JPY | 1.26% |
| 2019 Q4 | 39.86 Billion JPY | 14.48% |
| 2019 FY | 143.26 Billion JPY | 3.39% |
| 2019 Q1 | 33.46 Billion JPY | -7.37% |
| 2019 Q2 | 35.11 Billion JPY | 4.93% |
| 2019 Q3 | 34.82 Billion JPY | -0.82% |
| 2018 Q2 | 33.43 Billion JPY | -2.71% |
| 2018 FY | 138.56 Billion JPY | 11.63% |
| 2018 Q4 | 36.12 Billion JPY | 4.28% |
| 2018 Q3 | 34.63 Billion JPY | 3.59% |
| 2018 Q1 | 34.36 Billion JPY | 10.52% |
| 2017 FY | 124.13 Billion JPY | 1.36% |
| 2017 Q4 | 31.09 Billion JPY | -2.95% |
| 2017 Q3 | 32.04 Billion JPY | 9.05% |
| 2017 Q2 | 29.38 Billion JPY | -7.05% |
| 2017 Q1 | 31.61 Billion JPY | 5.41% |
| 2016 Q4 | 29.98 Billion JPY | -3.58% |
| 2016 Q2 | 31.26 Billion JPY | 3.85% |
| 2016 FY | 122.46 Billion JPY | 16.12% |
| 2016 Q1 | 30.1 Billion JPY | 0.07% |
| 2016 Q3 | 31.1 Billion JPY | -0.52% |
| 2015 FY | 105.45 Billion JPY | 16.45% |
| 2015 Q3 | 30.04 Billion JPY | 19.05% |
| 2015 Q1 | 20.09 Billion JPY | -16.9% |
| 2015 Q2 | 25.23 Billion JPY | 25.55% |
| 2015 Q4 | 30.08 Billion JPY | 0.15% |
| 2014 Q2 | 21.29 Billion JPY | 2.29% |
| 2014 Q3 | 24.27 Billion JPY | 14.01% |
| 2014 Q4 | 24.18 Billion JPY | -0.36% |
| 2014 FY | 90.55 Billion JPY | 16.75% |
| 2014 Q1 | 20.81 Billion JPY | 10.15% |
| 2013 Q1 | 18.51 Billion JPY | -5.29% |
| 2013 Q2 | 19.38 Billion JPY | 4.72% |
| 2013 Q3 | 20.77 Billion JPY | 7.18% |
| 2013 FY | 77.56 Billion JPY | -1.85% |
| 2013 Q4 | 18.89 Billion JPY | -9.05% |
| 2012 FY | 79.03 Billion JPY | 3.48% |
| 2012 Q4 | 19.54 Billion JPY | -4.51% |
| 2012 Q1 | 19.19 Billion JPY | -6.17% |
| 2012 Q3 | 20.46 Billion JPY | 3.24% |
| 2012 Q2 | 19.82 Billion JPY | 3.26% |
| 2011 Q1 | 17.67 Billion JPY | 8.78% |
| 2011 Q4 | 20.46 Billion JPY | 5.27% |
| 2011 FY | 76.37 Billion JPY | 0.65% |
| 2011 Q2 | 18.8 Billion JPY | 6.42% |
| 2011 Q3 | 19.43 Billion JPY | 3.35% |
| 2010 Q1 | 20.71 Billion JPY | 38.62% |
| 2010 FY | 75.88 Billion JPY | 15.55% |
| 2010 Q4 | 16.24 Billion JPY | -11.15% |
| 2010 Q2 | 20.63 Billion JPY | -0.38% |
| 2010 Q3 | 18.28 Billion JPY | -11.41% |
| 2009 FY | 65.67 Billion JPY | -1.81% |
| 2009 Q2 | 17.47 Billion JPY | 0.0% |
| 2009 Q3 | 16.93 Billion JPY | -3.1% |
| 2009 Q4 | 14.94 Billion JPY | -11.74% |
| 2008 FY | 66.88 Billion JPY | 2.89% |
| 2007 FY | 65 Billion JPY | 1.78% |
| 2006 FY | 63.86 Billion JPY | 8.27% |
| 2005 FY | 58.98 Billion JPY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AstraZeneca PLC | 34.69 Billion USD | -372.358% |
| Bristol-Myers Squibb Company PFD CONV 2 | 34.31 Billion USD | -377.592% |
| CSPC Pharmaceutical Group Limited | 30.13 Billion USD | -443.749% |
| Clarus Therapeutics Holdings, Inc. | 11.23 Million USD | -1458260.772% |
| Novartis AG | 34.18 Billion USD | -379.338% |
| PT Kalbe Farma Tbk. | 743.47 Million USD | -21941.953% |